- Determine the clinical response rate of patients who have an immediate need to receive
interleukin-2 (IL-2) in addition to this vaccine.

- Compare the immunologic response, in terms of changes in T-cell precursors before and
after treatment, in patients treated with this vaccine with or without IL-2.

- Compare the toxicity profile of these regimens in these patients.

OUTLINE: This is a randomized, open-label study.

Patients who need immediate interleukin-2 (IL-2) receive tyrosinase-related protein-2
(TRP-2):180-188 peptide vaccine emulsified with Montanide ISA-51 on day 1 and high-dose IL-2
IV over 15 minutes once every 8 hours on days 2-5. Treatment repeats every 3 weeks for up to
4 courses in the absence of disease progression or unacceptable toxicity.

Patients who do not need immediate IL-2 are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive TRP-2:180-188 peptide vaccine emulsified with Montanide ISA-51
subcutaneously (SC) on day 1. Treatment repeats every 3 weeks for up to 4 courses in
the absence of disease progression or unacceptable toxicity.

Patients who have a complete response (CR) receive 1 additional course after achieving CR.
Patients who have progressive disease while receiving vaccine alone may cross over to
receive peptide vaccine with IL-2 for at least 2 courses.

Patients are followed at 3 weeks.

PROJECTED ACCRUAL: A maximum of 83 patients (19-33 who need immediate interleukin-2 (IL-2);
15-25 per treatment arm who do not need immediate IL-2) will be accrued for this study
within 1 year.

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.